Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the
Cells | Free Full-Text | Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
Frontiers | Cardiovascular toxicity from therapies for light chain amyloidosis
Treatment schema for newly diagnosed multiple myeloma and commonly used... | Download Scientific Diagram
What is the clinical value of adding daratumumab to CyBorD in the treatment of light-chain amyloidosis? Results from phase III ANDROMEDA study
Figure 3, Inverse Probability Weighted Kaplan-Meier Plot of MOD-PFS Based on IRC Assessment — ITT Population - Daratumumab (Darzalex SC) - NCBI Bookshelf
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment - ScienceDirect
Keith Stockerl-Goldstein, MD 😷 on X: "RT @SLentzsch: My favorite topic #amyloidosis: Update on Andromeda Dara-CyBorD vs CyBorD by Ray Comenzo ➡️ Dara-CyBorD results in longer PFS…" / X
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA - ScienceDirect
Second- and third-line treatment strategies in multiple myeloma: a referral-center experience | Blood Cancer Journal
Multiple Myeloma Hub on X: "CONGRESS | #EHA25virtual | Results from the ANDROMEDA study comparing SC Dara + CyBorD vs CyBorD alone in patients with AL amyloidosis, reported by Efstathios Kastritis @uoaofficial,
Dara-CyBorD Treatment – ASG Webinar 1/13 | oneAMYLOIDOSISvoice
Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, E | CMAR
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
Informe de Posición de la SEHH
Survival of 230 patients with AL amyloidosis treated with CyBorD. After... | Download Scientific Diagram
Dara-CyBorD Treatment – ASG Webinar 1/13 | oneAMYLOIDOSISvoice
Multiple Myeloma Hub on X: "Dara-CyBorD delayed MOD-PFS, improved organ response at six months, and had an acceptable safety profile. #mmsm https://t.co/HHLRt13kTR" / X
Results of using dara-CyBorD to treat patients with newly diagnosed or relapsed multiple myeloma
The current SOC in AL amyloidosis: dara-CyBorD & considerations for patients with relapsed disease | VJHemOnc
Multiple Myeloma Hub on X: "CONGRESS | #EHA24 | Raymond L Comenzo, @tuftsmedicalctr presented the ANDROMEDA trial of dara-SC + cyclophosphamide + bortezomib + dexamethasone (CYBORD) in light-chain amyloidosis #mmsm #myeloma #EHA2019 @
CyborD-DARA combination in first-line treatment for multiple myeloma | VJHemOnc
Current Oncology | Free Full-Text | Management of Multiple Myeloma: A Review for General Practitioners in Oncology
